HUP0400645A2 - NMDA-receptor agonistát tartalmazó gyógyászati készítmények - Google Patents

NMDA-receptor agonistát tartalmazó gyógyászati készítmények

Info

Publication number
HUP0400645A2
HUP0400645A2 HU0400645A HUP0400645A HUP0400645A2 HU P0400645 A2 HUP0400645 A2 HU P0400645A2 HU 0400645 A HU0400645 A HU 0400645A HU P0400645 A HUP0400645 A HU P0400645A HU P0400645 A2 HUP0400645 A2 HU P0400645A2
Authority
HU
Hungary
Prior art keywords
disease
contain
dementia
preparations
hydroxy4
Prior art date
Application number
HU0400645A
Other languages
English (en)
Inventor
Jinyang Hong
Yesook Kim
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0400645A2 publication Critical patent/HUP0400645A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány olyan, stabil gyógyászati készítményekre vonatkozik,amelyek hatóanyagként egy N-metil-D-aszparaginsav (NMDA) receptorantagonistát, azaz (1S,2S)-1-(4-hidroxifenil)-2(4-hidroxi4-fenilpiperidin-l-il)-1-propanolt tartalmaznak. A találmány szerintigyógyászati készítmények felhasználhatók sztrók, a gerincvelősérülései, traumás agysérülések, multiinfarktusos demencia, a központiidegrendszer degeneratív megbetegedései, így például Alzheimer-kór,Alzheimer-típusú öregkori demencia, Huntington-kór, Parkinson-kór,epilepszia, amiotrófiás egyoldali szklerózis, fájdalom, AIDSkövetkeztében fellépő demencia, pszichotikus állapotok, kábítószerhezvaló hozzászokás, migrén, hipoglükémia, azaz alacsony vércukorszint,szorongásos állapotok, vizelet-visszatartási nehézségek és a központiidegrendszerben végrehajtott sebészeti beavatkozás, úgynevezettnyitottszíves sebészeti beavatkozás vagy bármely olyan más eljáráskövetkeztében fellépő ischémiás esemény kezelésére, amelynek során akardiovaszkuláris rendszer funkciója sérülést szenved. A találmányszerinti készítményekre az jellemző, hogy farmakológiailag hatásosmennyiségben (1S,2S)-1-(4-hidroxifenil)-2-(4-hidroxi4-fenilpiperidin-l-il)-1-propanolt vagy ennek gyógyászatilag elfogadható sóját és vizettartalmaznak, mimellett az ilyen készítméryek kevesebb, mintkörülbelül 2 p.p.m. mennyiségű szabad réziont és kevesebb mintkörülbelül 2 p.p.m. szabad vasiont tartalmaznak. Ó
HU0400645A 2000-12-13 2001-12-05 NMDA-receptor agonistát tartalmazó gyógyászati készítmények HUP0400645A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25537200P 2000-12-13 2000-12-13
PCT/IB2001/002359 WO2002047685A2 (en) 2000-12-13 2001-12-05 Nmda receptor agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HUP0400645A2 true HUP0400645A2 (hu) 2004-06-28

Family

ID=22968017

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400645A HUP0400645A2 (hu) 2000-12-13 2001-12-05 NMDA-receptor agonistát tartalmazó gyógyászati készítmények

Country Status (42)

Country Link
US (2) US6635270B2 (hu)
EP (1) EP1347760B1 (hu)
JP (1) JP2004515529A (hu)
KR (1) KR100533407B1 (hu)
CN (1) CN1273135C (hu)
AP (1) AP1235A (hu)
AR (1) AR035607A1 (hu)
AT (1) ATE296629T1 (hu)
AU (2) AU1845402A (hu)
BG (1) BG107788A (hu)
BR (1) BR0116085A (hu)
CA (1) CA2431172A1 (hu)
CZ (1) CZ20031543A3 (hu)
DE (1) DE60111265T2 (hu)
DO (1) DOP2001000300A (hu)
DZ (1) DZ3484A1 (hu)
EA (1) EA006489B1 (hu)
EC (1) ECSP034655A (hu)
EE (1) EE200300284A (hu)
ES (1) ES2239648T3 (hu)
GE (1) GEP20053568B (hu)
HK (1) HK1059575A1 (hu)
HR (1) HRP20030473A2 (hu)
HU (1) HUP0400645A2 (hu)
IL (1) IL155810A0 (hu)
IS (1) IS6811A (hu)
MA (1) MA26970A1 (hu)
MX (1) MXPA03005257A (hu)
NO (1) NO20032678L (hu)
NZ (1) NZ525742A (hu)
OA (1) OA12414A (hu)
PA (1) PA8534901A1 (hu)
PE (1) PE20020710A1 (hu)
PL (1) PL362080A1 (hu)
PT (1) PT1347760E (hu)
SK (1) SK6982003A3 (hu)
TN (1) TNSN01173A1 (hu)
UA (1) UA73619C2 (hu)
UY (1) UY27068A1 (hu)
WO (1) WO2002047685A2 (hu)
YU (1) YU41103A (hu)
ZA (1) ZA200303892B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2368554B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10,11-二氢-5H-二苯并〔a,d〕环庚烯-5,10-亚胺在制备避孕药物中的应用
ES2553968T3 (es) 2008-09-18 2015-12-15 Northwestern University Moduladores del receptor NMDA y sus usos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
MX2012009388A (es) 2010-02-11 2012-10-01 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato estabilizado de estructura secundaria y sus usos.
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2015009772A (es) 2013-01-29 2016-05-31 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
KR102280616B1 (ko) 2013-01-29 2021-07-21 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN105229010A (zh) 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105934247A (zh) * 2013-12-23 2016-09-07 株式会社三养生物制药 包含帕洛诺司琼的药物组合物
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
OA12414A (en) 2006-04-18
MA26970A1 (fr) 2004-12-20
CN1273135C (zh) 2006-09-06
HK1059575A1 (en) 2004-07-09
CA2431172A1 (en) 2002-06-20
KR100533407B1 (ko) 2005-12-02
YU41103A (sh) 2006-05-25
US6635270B2 (en) 2003-10-21
EP1347760A2 (en) 2003-10-01
UA73619C2 (en) 2005-08-15
WO2002047685A2 (en) 2002-06-20
DE60111265D1 (de) 2005-07-07
PL362080A1 (en) 2004-10-18
NO20032678D0 (no) 2003-06-12
CZ20031543A3 (cs) 2004-06-16
PT1347760E (pt) 2005-09-30
EP1347760B1 (en) 2005-06-01
AP1235A (en) 2004-01-06
ATE296629T1 (de) 2005-06-15
TNSN01173A1 (fr) 2005-11-10
UY27068A1 (es) 2002-07-31
US20040039022A1 (en) 2004-02-26
ES2239648T3 (es) 2005-10-01
MXPA03005257A (es) 2003-09-25
AU1845402A (en) 2002-06-24
NO20032678L (no) 2003-06-12
DOP2001000300A (es) 2002-05-30
DE60111265T2 (de) 2006-05-04
PA8534901A1 (es) 2002-08-26
EE200300284A (et) 2003-10-15
BG107788A (bg) 2004-01-30
JP2004515529A (ja) 2004-05-27
AU2002218454B2 (en) 2005-10-27
AR035607A1 (es) 2004-06-16
AP2001002376A0 (en) 2001-12-31
PE20020710A1 (es) 2002-08-09
GEP20053568B (en) 2005-07-11
HRP20030473A2 (en) 2005-04-30
IS6811A (is) 2003-05-08
US20020111366A1 (en) 2002-08-15
KR20030070060A (ko) 2003-08-27
BR0116085A (pt) 2003-12-23
WO2002047685A3 (en) 2002-08-15
ECSP034655A (es) 2003-07-25
CN1479617A (zh) 2004-03-03
EA006489B1 (ru) 2005-12-29
IL155810A0 (en) 2003-12-23
ZA200303892B (en) 2004-05-20
SK6982003A3 (en) 2004-08-03
NZ525742A (en) 2005-07-29
DZ3484A1 (fr) 2002-06-20
EA200300514A1 (ru) 2003-10-30

Similar Documents

Publication Publication Date Title
HUP0400645A2 (hu) NMDA-receptor agonistát tartalmazó gyógyászati készítmények
ES2284740T3 (es) Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.
CA2545503C (en) Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2433585A1 (en) Pharmaceutical compositions containing donepezil hydrochloride
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
EA200970148A1 (ru) Фармацевтический состав, содержащий донепезил
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
JP2003520193A (ja) R(−)−ケトプロフェンを用いる神経障害性疼痛、耳鳴り、およびその他の障害治療のための方法および組成物
WO2007073560A3 (en) Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
TW201116273A (en) Co-crystals of tramadol and coxibs
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
CN105792821A (zh) 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂
AU705419B2 (en) Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
JP2004524357A5 (hu)
TWI290831B (en) Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient
KR102254542B1 (ko) 과다운동성 운동 장애의 예방 및/또는 치료에 사용하기 위한 치료제
AP2001002119A0 (en) Sertraline oral concentrate.
JP2005187328A (ja) イブプロフェン含有解熱鎮痛組成物、及び感冒薬
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
CN109966278B (zh) 草酰苹果酸在制备治疗神经细胞损伤的药物中的应用
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
JPH0840902A (ja) 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees